Peptides Or Polypeptides, Or Derivatives Thereof Patents (Class 506/18)
  • Patent number: 11874282
    Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 16, 2024
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Martin Hund, Edelgard Anna Kaiser, Ursula-Henrike Wienhues-Thelen, Dirk Block, Johann Karl
  • Patent number: 11867700
    Abstract: The present disclosure relates to methods of identifying components present in intact lipoprotein particles. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subtypes and subpopulations that exist within lipoprotein density classes are determined based on simultaneously measured m/z and charge of ionized lipoprotein particles.
    Type: Grant
    Filed: April 11, 2023
    Date of Patent: January 9, 2024
    Assignee: THE TRUSTEES OF INDIANA UNIVERSITY
    Inventors: Martin F. Jarrold, Corrine A. Lutomski
  • Patent number: 11830582
    Abstract: Provided herein are methods implemented by a processor in a computer for designing a clamp peptide comprising the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2. Also provided herein are computer-readable storage media having stored thereon machine-readable instructions executable by a processor and systems. Related methods of manufacturing a clamp peptide and the clamp peptides manufactures by the methods are provided.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 28, 2023
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Sylvia Daunert, Sapna K. Deo, Emre Dikici, Marcello Mascini
  • Patent number: 11814672
    Abstract: The present invention provides a complex of LNA probe and graphene oxide, and a nucleic acid detection method using the same. In the present invention, LNA-containing molecular beacon is conjugated through covalent bonding with graphene oxide, a single strand of the molecular beacon binds to a target nucleic acid to form a complex, and the complex is separated from graphene oxide to induce a fluorescence signal. The molecular beacon and graphene oxide can be covalently bonded to minimize non-specific signals, and a LNA-added molecular beacon is designed in a double strand to detect a very low concentration of target nucleic acid with high sensitivity, as well as a fluorescent signal, and the multiple target nucleic acids can be detected simultaneously through diversification of the fluorescent signal to enable easy and accurate detection of a nucleic acid biomarker whose specific expression level is specifically changed according to diseases and disease progression.
    Type: Grant
    Filed: August 30, 2020
    Date of Patent: November 14, 2023
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Jieon Lee, Woo-keun Kim, Seokjoo Yoon, Bomi Shin
  • Patent number: 11749513
    Abstract: A prefabricated polymeric layer to be used in a matrix-assisted laser desorption/ionization (MALDI) based system, the prefabricated polymeric layer including a first sublayer; and a second sublayer attached to the first sublayer, wherein the second sublayer includes a sample holder. At least one of the first sublayer and the second first sublayer includes a polymeric material, and the prefabricated polymeric layer is to be added to a target material to be examined by the MALDI system.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 5, 2023
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Dominik Ludewig Michels, Franziska Lissel
  • Patent number: 11668719
    Abstract: The present disclosure relates to a method of identifying components present in a lipoprotein. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subpopulations that exist within lipoprotein classes are determined by correlating m/z and mass.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 6, 2023
    Assignee: The Trustees Of Indiana University
    Inventors: Martin F. Jarrold, Corrine A. Lutomski
  • Patent number: 11639933
    Abstract: Methods of detecting a target in a sample are provided. Kits for performing the methods described herein are also provided.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: May 2, 2023
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Boaz Gildor, Dalia Shezifi
  • Patent number: 11634488
    Abstract: The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti-CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: April 25, 2023
    Assignee: INTERNATIONAL—DRUG—DEVELOPMENT—BIOTECH
    Inventors: Claudine Vermot-Desroches, Chanthy Kong-Flohr, Marc Godinat, Bruno Cavallini
  • Patent number: 11613569
    Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: March 28, 2023
    Assignees: CZ Biohub SF, LLC., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Derek Croote, Stephen R. Quake, Kari Nadeau, Spyros Darmanis, David N. Cornfield
  • Patent number: 11605460
    Abstract: Disclosed is a non-invasive method for assessing in a subject the presence and severity of a liver lesion, or the risk of death or liver-related events, including: 1) performing at least three binary logistic regressions on at least one variable, performed on the same variable(s) but each directed to a different single diagnostic target, thereby obtaining at least three scores; 2) combining the scores from step 1) in a multiple linear regression to obtain a new multi-targeted score; 3) optionally sorting the multi-targeted score obtained in step 2) in a classification of liver lesion stages or grades, thereby determining to which liver lesion stage or grade the subject belongs based on his/her multi-targeted score. Also disclosed is a single multi-targeted non-invasive test obtained by the combination of single-targeted non-invasive tests providing a unique score and a unique classification with improved accuracy compared to single-targeted diagnostic tests.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: March 14, 2023
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITÉ D'ANGERS
    Inventor: Paul Calès
  • Patent number: 11584781
    Abstract: The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.
    Type: Grant
    Filed: December 29, 2021
    Date of Patent: February 21, 2023
    Assignee: ELIGO BIOSCIENCE
    Inventors: Jesus Fernandez Rodriguez, Xavier Duportet
  • Patent number: 11525831
    Abstract: Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: December 13, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Joshua LaBaer, Jie Wang, Ji Qui, Garrick Wallstrom, Karen Anderson, Jin Park, Jonine Figueroa
  • Patent number: 11471888
    Abstract: Described herein are digital microfluidic (DMF) devices and corresponding methods for managing reagent solution evaporation during a reaction. Reactions on the DMF devices described here are performed in an air or gas matrix. The DMF devices include a means for performing reactions at different temperatures. To address the issue of evaporation of the reaction droplet especially when the reaction is performed at higher temperatures, a means for introducing a replenishing droplet has been incorporated into the DMF device. A replenishing droplet is introduced every time when it has been determined that the reaction droplet has fallen below a threshold volume. Detection and monitoring of the reaction droplet may be through visual, optical, fluorescence, colorimetric, and/or electrical means.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 18, 2022
    Assignee: mirOculus Inc.
    Inventors: Mais J. Jebrail, Ronald Francis Renzi, Steven Branda
  • Patent number: 11318467
    Abstract: Embodiments include assay devices within a single use, disposable cassette for biochemical assays with at least one fluid well and at least one capillary valve. The capillary valve in combination with motion of porous sheets within the assay leads to addition of liquid reagents at different times to the assay although a user adds the liquid reagents to the cassette simultaneously.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: May 3, 2022
    Assignee: Tokitae LLC
    Inventors: Caitlin E. Anderson, Joshua Davis Bishop, David Michael Cate, Benjamin David Grant, Toan Huynh, Damian Madan, Kevin Paul Flood Nichols, Bernhard Hans Weigl
  • Patent number: 11174509
    Abstract: The invention generally relates to methods for distinguishing a rare genetic variation in a nucleic acid sequence.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: November 16, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Darren R. Link, Michael L. Samuels
  • Patent number: 11124577
    Abstract: The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: September 21, 2021
    Assignee: ENGMAB SÀRL
    Inventors: Minh Diem Vu, Klaus Strein, Bruno David Lourenco Paiva, Jesus Fernado San Miguel Izquierdo
  • Patent number: 11103167
    Abstract: Presented are systems and methods that perform noninvasive glucose monitoring using mid-infrared self-emission of the human body that acts as a background radiation emitter. Various embodiments accomplish this by taking advantage of the guided-mode resonance (GMR) effect in a number of bandpass filters that are constructed as an array of coplanar filters. The filter array acts as a spectral separator that uses a grating layer and a thin film waveguide to form reflection and transmission filters for particular wavelengths. Unlike, common multi-layer optical filter designs that utilize numerous individual optical filters, a novel GMR filter design comprises an array of filters that may be fabricated from CMOS-compatible materials using only a few thin film and grating layers to filter light. Advantageously, this reduces manufacturing cost and allows for simultaneous monitoring of a number of wavelengths of the glucose spectrum.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 31, 2021
    Inventors: Yen-Chun Yeh, Sheng Yang, Dominik J. Schmidt
  • Patent number: 11085038
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: August 10, 2021
    Assignee: MORPHOSYS AG
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Patent number: 10995133
    Abstract: Disclosed is an antibody in which the 80th amino acid residue in a variable region based on the Kabat method and the 171th amino acid residue in a constant region based on the Kabat method are substituted with cysteine in an antibody in which the 80th amino acid residue in the variable region and the 171th amino acid residue in the constant region are not cysteine.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 4, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Nobuyuki Ide, Tomofumi Nakada
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 10899798
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: January 26, 2021
    Assignee: BicycleRD Limited
    Inventors: Gavin Bennett, Daniel Paul Teufel
  • Patent number: 10802019
    Abstract: The invention relates to methods of determining whether or not an individual has or is likely to develop a neurological disease and related methods and kits.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 13, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Angela Vincent, Philippa Pettingill, Patrick Waters
  • Patent number: 10655125
    Abstract: The invention relates to novel polypeptide libraries that are conformationally constrained in an anti-parallel, helix-turn-helix arrangement. The invention further relates to methods of generating and screening such libraries for biological, pharmaceutical and other uses.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 19, 2020
    Assignee: MOR0059US.NP
    Inventors: Roger Müller, Andreas Bültmann, Josef Prassler, Markus Moosmeier
  • Patent number: 9664693
    Abstract: Methods and kits for characterizing liver damage in an individual are provided. The methods employ the use of immune analytes as biomarkers for detecting liver damage and predicting the likelihood that an individual suffering from liver damage will experience life-threatening liver failure. Concentration values for serum albumin and other identified immune analytes are obtained or determined from a blood sample taken from the individual. The obtained concentration values are then compared to corresponding concentrations from individuals having a healthy liver. By comparing the concentrations, an individual's likelihood of developing life-threatening liver failure and needing a liver transplant within a given time period (e.g., 6 months) can be identified.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 30, 2017
    Assignee: THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
    Inventors: Herbert L. Bonkovsky, David Foureau, H. James Norton, Nury Steuerwald
  • Patent number: 9346892
    Abstract: An oligopeptide microarray and methods for the synthesis thereof are presented. Further presented is a microarray on a solid support comprising at least about 10,000 oligopeptide features per cm2 and preferably at least about 50,000 oligopeptide features per cm2.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: May 24, 2016
    Assignee: ROCHE NIMBLE GEN, INC.
    Inventors: Tom Albert, Todd Richmond, Matthew Rodesch, Klaus-Peter Stengele, Jochen Buehler, Markus Ott
  • Patent number: 9250233
    Abstract: Methods for detection of any antibody utilizing a standardized approach applicable to any antibody which provides highly specific assays specific for individual or multiple antibodies. The methods enable improved pharmacokinetic analysis during development and clinical use of antibody-based therapies as well as determination of diagnostic and/or prognostic factors.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: February 2, 2016
    Assignee: The Regents of the University of California
    Inventors: Thomas J. Kipps, Bradley T. Messmer, Ana B. Sanchez, Andrew C. Kummel, Manuel Ruidiaz
  • Patent number: 9175421
    Abstract: Provided is a method for determining one or more kinetic parameters of binding between a first binding member and a second binding member. The method includes adsorbing the first binding member to a surface at a plurality of microspots. The second binding member is then presented to the first binding member at each of the microspots, there being a plurality of combinations of first binding member surface density and second binding member concentration among the plurality of microspots. Data indicative of a binding reaction between the first of microspots are then obtained and analyzed so as to obtain one or more kinetic parameters of the binding between the first and second binding members. Also provided is a system for carrying out the method. A method for localizing a molecular species at microspots on a surface, and a probe array produced by the method are also provided.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 3, 2015
    Assignee: Bio-Rad Haifa Ltd.
    Inventors: Ariel Notcovich, Alon Herschhorn, Shai Nimri, John Barich, Ariel Lipson, Ran Boaz, Doron Lipson, Yaakov Levie
  • Patent number: 9168329
    Abstract: The present invention is directed to the design, synthesis and use of various ?-peptides exhibiting antifungal activity. The ?-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: October 27, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sean P. Palecek, Samuel H. Gellman, William C. Pomerantz, Amy J. Karlsson
  • Patent number: 9114189
    Abstract: A modified or isolated composition comprising a gel. The gel includes a plurality of first polymers, each of said first polymers having first functional groups comprising a first nucleic acid sequence attached as side-chains thereto. The gel includes a plurality of second polymers, each of said second polymers having second functional groups comprising a second nucleic acid sequence attached as side-chains thereto, said first and said second functional groups forming a reversible cross-link between said first and said second polymers, wherein said cross-link comprises a plurality of hydrogen bonds between complementary base portions of said first and said second nucleic acid sequences.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: August 25, 2015
    Assignee: Alcatel Lucent
    Inventors: Allen P. Mills, Jr., Bernard Yurke
  • Publication number: 20150148254
    Abstract: The present invention provides methods and compositions for prognosing treatment outcome in DLBCL patients, diagnosing DLBCL and monitoring efficacy of DLBCL treatment.
    Type: Application
    Filed: November 29, 2014
    Publication date: May 28, 2015
    Inventors: Lisa M. Rimsza, Michael L. Leblanc, Joseph M. Unger
  • Publication number: 20150148247
    Abstract: The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.
    Type: Application
    Filed: May 24, 2013
    Publication date: May 28, 2015
    Applicants: The Broad Institute, Inc., The General Hospital Corporati d/b/a Massachusetts General Hospital
    Inventors: Rushdy Ahmad, Michael Gillette, Steven A. Carr
  • Publication number: 20150148245
    Abstract: Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 28, 2015
    Applicant: Nogra Pharma Limited
    Inventors: Giovanni Monteleone, Francesca Viti, Salvatore Bellinvia
  • Publication number: 20150141325
    Abstract: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the ?E pathway in Escherichia coli.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 21, 2015
    Inventors: Sarah Ellen Ades, Kenneth Charles Keiler
  • Publication number: 20150141279
    Abstract: A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-?, TNF-?, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-?2, fractalkine, IFN-?, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1?, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1?, IL-6, GM-CSF, IL-1?, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-?, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.
    Type: Application
    Filed: May 27, 2013
    Publication date: May 21, 2015
    Applicant: Stellenbosch University
    Inventors: Gerhard Walzl, Novel Njweipi Chegou, Paulin Essone Ndong
  • Publication number: 20150139980
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 21, 2015
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Publication number: 20150141266
    Abstract: Methods, compositions and arrays for non-random loading of single analyte molecules into array structures are provided. For example, methods are presented for providing a surface comprising the plurality of array regions by exposing the surface to a solution comprising polymerase enzymes where each polymerase enzyme is bound to a binding structure having several functional moieties. The functional moieties of the binding structure react with the binding elements on the array regions such that the functional moieties on the binding structure react with other available binding sites in an array region, preventing other polymerase-binding structures from loading, and resulting in a single polymerase molecule bound to each of these regions.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Turner, Benjamin Flusberg, Lei Sun
  • Publication number: 20150141276
    Abstract: The present description relates to an in vitro method for the diagnosis of endometriosis, an in vitro method for the monitoring of endometriosis and a kit for the diagnosis of endometriosis and/or for the monitoring of endometriosis in a subject.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 21, 2015
    Inventors: Pietro Giulio Signorile, Alfonso Baldi
  • Publication number: 20150141260
    Abstract: This invention provides methods of using circulating diseased cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using circulating diseased cells to identify markers of diseases or conditions. This invention also provides methods for assessing the risk of developing a disease or condition, prognosing said disease, monitoring said disease progression or regression, assessing the efficacy of a treatment, or identifying a compound capable of ameliorating or treating said disease or condition.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 21, 2015
    Inventor: Harry STYLLI
  • Publication number: 20150133322
    Abstract: The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 14, 2015
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean Roudier, Isabelle Auger
  • Publication number: 20150133342
    Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Inventors: Sun W. Tam, Ying Xu, Patrick J. Muraca
  • Publication number: 20150133327
    Abstract: The present invention provides methods identifying subjects having prostate cancer (PCa) by detecting in micro-particles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having PCa from those having non-malignant prostate pathologies, including benign prostatic hyperplasia. Methods for monitoring prostate cancer and assessing efficacy of prostate cancer therapies are also disclosed. Kits for detecting prostate cancer using the methods disclosed are also provided.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Hon Sing LEONG, Colleen Nicole BIGGS
  • Publication number: 20150133308
    Abstract: The present invention relates to a method for improving a repebody protein comprising repeat modules and a nucleotide library encoding a repebody protein library for improving the repebody protein. More particularly, the present invention relates to a method for improving a repebody protein using a module evolution method of sequentially mutating repeat modules constituting the repebody protein, and a nucleotide library encoding a repebody protein library used to improve the protein. According to the module evolution method of the present invention, an improved repebody protein can be screened which has a high binding affinity and accordingly increased specificity and activity, and thus it is easy to express a repebody used as an inhibitor, a therapeutic agent, and an analysis means against a target substance.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Inventors: Hak-Sung Kim, Joong-Jae Lee, Hyun-Ho Kyeong, Jung-Min Choi, Da-Eun Hwang, Hae-Kap Cheong, Hyun Jung Kim, Eun-Kyeong Jo, Chul-Su Yang, Jae-Min Yuk
  • Publication number: 20150133305
    Abstract: The present invention is directed to methods, for example phage display assays, for bioengineering peptides that bind to individual distinct nucleotides. Also provided are peptides engineered by such methods. Specifically, cyclic peptides that bind individual distinct nucleotides are provided herein.
    Type: Application
    Filed: November 7, 2008
    Publication date: May 14, 2015
    Inventors: Mineo Yamakawa, Joseph V. Kosmoski, Deane C. Little
  • Publication number: 20150126408
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Application
    Filed: January 15, 2015
    Publication date: May 7, 2015
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Publication number: 20150126407
    Abstract: This invention provides high unit density arrays of microparticles and methods of assembling such arrays. The microparticles in the arrays may be functionalized with chemical or biological entities specific to a given target analyte. The high unit density arrays of this invention are formed on chips which may be combined to form multichip arrays according to the methods described herein. The chips and/or multichip arrays of this invention are useful for chemical and biological assays.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Michael Seul, Chiu Wo Chau, Hui Huang, Sukanta Banerjee, Jiacheng Yang, Ye Hong
  • Publication number: 20150126388
    Abstract: A surface enhanced Raman spectroscopy (SERS) marker conjugate is provided. The SERS marker conjugate comprises a metallic nanoparticle and an organometallic material attached to a surface of the metallic nanoparticle. A biosensor comprising a plurality of the SERS marker conjugates and a method of forming the SERS marker conjugate is also provided.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 7, 2015
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Kien Voon Kong, Malini Olivo, Weng Kee Leong, Zhiyong Lam
  • Publication number: 20150126385
    Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.
    Type: Application
    Filed: December 3, 2012
    Publication date: May 7, 2015
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: John Lamont, Ivan Mc Connell, Peter Fitzgerald
  • Publication number: 20150126394
    Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: James W. LILLARD, JR., Rajesh Singh, Shailesh Singh
  • Publication number: 20150126384
    Abstract: The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 7, 2015
    Applicant: VERMILLION, INC.
    Inventors: Estrid Hogdall, Eric T. Fung, Jarle IB Christensen, Claus Hogdall
  • Publication number: 20150126386
    Abstract: The present invention relates to a method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample, which involves: a) determining the quantity of at least one marker, and b) comparing the quantity with a reference quantity obtained from a group of individuals who have been diagnosed with non-severe dengue, and if the quantity determined in step a) is greater than the reference quantity established in step b), predicting that the patient will develop severe dengue, and also to the use of predictive marker(s) and to a kit to predict the development of severe dengue.
    Type: Application
    Filed: January 23, 2013
    Publication date: May 7, 2015
    Inventor: Frédéric Bedin